Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
Sci-Reasoning: A Dataset Decoding AI Innovation Patterns
arXiv:2601.04577v1 Announce Type: new Abstract: While AI innovation accelerates rapidly, the intellectual process behind breakthroughs -- how researchers identify gaps, synthesize prior work, and generate insights -- remains poorly understood. The lack of structured data on scientific reasoning hinders systematic analysis and development of AI research agents. We introduce Sci-Reasoning, the first dataset capturing the intellectual synthesis behind high-quality AI research. Using community-vali
-
cs.AI, q-bio.NC updates on arXiv.org
-
Beyond Monolithic Architectures: A Multi-Agent Search and Knowledge Optimization Framework for Agentic Search
arXiv:2601.04703v1 Announce Type: new Abstract: Agentic search has emerged as a promising paradigm for complex information seeking by enabling Large Language Models (LLMs) to interleave reasoning with tool use. However, prevailing systems rely on monolithic agents that suffer from structural bottlenecks, including unconstrained reasoning outputs that inflate trajectories, sparse outcome-level rewards that complicate credit assignment, and stochastic search noise that destabilizes learning. To a
Beyond Monolithic Architectures: A Multi-Agent Search and Knowledge Optimization Framework for Agentic Search
-
cs.AI, q-bio.NC updates on arXiv.org
-
Balancing Usability and Compliance in AI Smart Devices: A Privacy-by-Design Audit of Google Home, Alexa, and Siri
arXiv:2601.04403v1 Announce Type: cross Abstract: This paper investigates the privacy and usability of AI-enabled smart devices commonly used by youth, focusing on Google Home Mini, Amazon Alexa, and Apple Siri. While these devices provide convenience and efficiency, they also raise privacy and transparency concerns due to their always-listening design and complex data management processes. The study proposes and applies a combined framework of Heuristic Evaluation, Personal Information Protect
Balancing Usability and Compliance in AI Smart Devices: A Privacy-by-Design Audit of Google Home, Alexa, and Siri
-
cs.AI, q-bio.NC updates on arXiv.org
-
Fast Mining and Dynamic Time-to-Event Prediction over Multi-sensor Data Streams
arXiv:2601.04741v1 Announce Type: cross Abstract: Given real-time sensor data streams obtained from machines, how can we continuously predict when a machine failure will occur? This work aims to continuously forecast the timing of future events by analyzing multi-sensor data streams. A key characteristic of real-world data streams is their dynamic nature, where the underlying patterns evolve over time. To address this, we present TimeCast, a dynamic prediction framework designed to adapt to the
Fast Mining and Dynamic Time-to-Event Prediction over Multi-sensor Data Streams
-
cs.AI, q-bio.NC updates on arXiv.org
-
Smart IoT-Based Wearable Device for Detection and Monitoring of Common Cow Diseases Using a Novel Machine Learning Technique
arXiv:2601.04761v1 Announce Type: cross Abstract: Manual observation and monitoring of individual cows for disease detection present significant challenges in large-scale farming operations, as the process is labor-intensive, time-consuming, and prone to reduced accuracy. The reliance on human observation often leads to delays in identifying symptoms, as the sheer number of animals can hinder timely attention to each cow. Consequently, the accuracy and precision of disease detection are signifi
Smart IoT-Based Wearable Device for Detection and Monitoring of Common Cow Diseases Using a Novel Machine Learning Technique
-
cs.AI, q-bio.NC updates on arXiv.org
-
Atlas 2 -- Foundation models for clinical deployment
arXiv:2601.05148v1 Announce Type: cross Abstract: Pathology foundation models substantially advanced the possibilities in computational pathology -- yet tradeoffs in terms of performance, robustness, and computational requirements remained, which limited their clinical deployment. In this report, we present Atlas 2, Atlas 2-B, and Atlas 2-S, three pathology vision foundation models which bridge these shortcomings by showing state-of-the-art performance in prediction performance, robustness, and
Atlas 2 -- Foundation models for clinical deployment
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Framework for Responsible AI Systems: Building Societal Trust through Domain Definition, Trustworthy AI Design, Auditability, Accountability, and Governance
arXiv:2503.04739v2 Announce Type: replace-cross Abstract: Responsible Artificial Intelligence (RAI) addresses the ethical and regulatory challenges of deploying AI systems in high-risk scenarios. This paper proposes a comprehensive framework for the design of an RAI system (RAIS) that integrates five key dimensions: domain definition, trustworthy AI design, auditability, accountability, and governance. Unlike prior work that treats these components in isolation, our proposal emphasizes their in
A Framework for Responsible AI Systems: Building Societal Trust through Domain Definition, Trustworthy AI Design, Auditability, Accountability, and Governance
-
cs.AI, q-bio.NC updates on arXiv.org
-
SciClaims: An End-to-End Generative System for Biomedical Claim Analysis
arXiv:2503.18526v2 Announce Type: replace-cross Abstract: We present SciClaims, an interactive web-based system for end-to-end scientific claim analysis in the biomedical domain. Designed for high-stakes use cases such as systematic literature reviews and patent validation, SciClaims extracts claims from text, retrieves relevant evidence from PubMed, and verifies their veracity. The system features a user-friendly interface where users can input scientific text and view extracted claims, predic
SciClaims: An End-to-End Generative System for Biomedical Claim Analysis
-
cs.AI, q-bio.NC updates on arXiv.org
-
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
arXiv:2512.00949v2 Announce Type: replace-cross Abstract: For patients undergoing systemic cancer therapy, the time between clinic visits is full of uncertainties and risks of unmonitored side effects. To bridge this gap in care, we developed and prospectively trialed a multi-modal AI framework for remote patient monitoring (RPM). This system integrates multi-modal data from the HALO-X platform, such as demographics, wearable sensors, daily surveys, and clinical events. Our observational trial
Multi-Modal AI for Remote Patient Monitoring in Cancer Care
-
Journal of Medical Internet Research
-
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
Background: Structured medication reviews (SMRs) are an essential component of medication optimization, especially for patients with multimorbidity and polypharmacy. However, the process remains challenging due to the complexities of patient data, time constraints, and the need for coordination among health care professionals (HCPs). This study explores HCPs’ perspectives on the integration of artificial intelligence (AI)–assisted tools to enhance the SMR process, with a focus on the potential b
Developing an AI-Assisted Tool That Identifies Patients With Multimorbidity and Complex Polypharmacy to Improve the Process of Medication Reviews: Qualitative Interview and Focus Group Study
-
Journal of Medical Internet Research
-
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
Background: The rapid growth of social media as an information channel has enabled the swift spread of inaccurate or false health information, significantly impacting public health. This widespread dissemination of misinformation has caused confusion, eroded trust in health authorities, led to noncompliance with health guidelines, and encouraged risky health behaviors. Understanding the dynamics of misinformation on social media is essential for devising effective public health communication str
Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
-
STAT

-
STAT+: OpenAI invites you to upload medical records to ChatGPT
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday. Millions of people, including me and possibly you, are already asking ChatGPT questions about health. Still others are dumping otherwise inscrutable medical records downloaded from patient portals into the generative AI bot, hoping to glean new insights. Now, OpenAI will encourage this behavior
STAT+: OpenAI invites you to upload medical records to ChatGPT
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your inbox every Tuesday and Thursday.
Millions of people, including me and possibly you, are already asking ChatGPT questions about health. Still others are dumping otherwise inscrutable medical records downloaded from patient portals into the generative AI bot, hoping to glean new insights.
Now, OpenAI will encourage this behavior with a new health specific tab in the service that the company says has better security and privacy protections so users feel safe pouring sensitive medical data into the bot. In addition to uploading files, users can hook up data from products like Apple Health and Weight Watchers or obtain medical records from providers through b.well’s network. OpenAI promises that it won’t train its models on the data you put into ChatGPT Health. (Reminder: Data that you upload to a consumer service is not covered by HIPAA.)
Continue to STAT+ to read the full story…


© Adobe
-
Journal of Medical Internet Research
-
National Institutes of Health–Funded Artificial Intelligence and Machine Learning Research, 2019‐2023: Cross-Sectional Study
Inflation-adjusted funding for ML/AI research increased by 233% between FY 2019 and 2023, outpacing the overall NIH budget increase of 12%.
National Institutes of Health–Funded Artificial Intelligence and Machine Learning Research, 2019‐2023: Cross-Sectional Study
-
Journal of Medical Internet Research
-
A Web-Based Cancer Prevention Intervention for Rural Emerging Adults: Mixed Methods Development and Pilot-Testing Study
Background: The rapid growth of user-generated web-based health information increases the complexity of cancer information seeking. One promising strategy for promoting high-quality cancer information consumption is through targeted interventions that are intentionally designed to reach individuals in the web-based spaces they occupy. However, there is a paucity of evidence-based information on the best strategies for designing and implementing web-based health behavior change interventions to i
A Web-Based Cancer Prevention Intervention for Rural Emerging Adults: Mixed Methods Development and Pilot-Testing Study
-
cs.AI, q-bio.NC updates on arXiv.org
-
A Proposed Paradigm for Imputing Missing Multi-Sensor Data in the Healthcare Domain
arXiv:2601.03565v1 Announce Type: cross Abstract: Chronic diseases such as diabetes pose significant management challenges, particularly due to the risk of complications like hypoglycemia, which require timely detection and intervention. Continuous health monitoring through wearable sensors offers a promising solution for early prediction of glycemic events. However, effective use of multisensor data is hindered by issues such as signal noise and frequent missing values. This study examines the
A Proposed Paradigm for Imputing Missing Multi-Sensor Data in the Healthcare Domain
-
cs.AI, q-bio.NC updates on arXiv.org
-
Clinical Data Goes MEDS? Let's OWL make sense of it
arXiv:2601.04164v1 Announce Type: cross Abstract: The application of machine learning on healthcare data is often hindered by the lack of standardized and semantically explicit representation, leading to limited interoperability and reproducibility across datasets and experiments. The Medical Event Data Standard (MEDS) addresses these issues by introducing a minimal, event-centric data model designed for reproducible machine-learning workflows from health data. However, MEDS is defined as a dat
Clinical Data Goes MEDS? Let's OWL make sense of it
-
npj Digital Medicine
-
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models
npj Digital Medicine, Published online: 07 January 2026; doi:10.1038/s41746-025-02324-4
An autonomous agentic workflow for clinical detection of cognitive concerns using large language models-
cs.AI, q-bio.NC updates on arXiv.org
-
The Path Ahead for Agentic AI: Challenges and Opportunities
arXiv:2601.02749v1 Announce Type: new Abstract: The evolution of Large Language Models (LLMs) from passive text generators to autonomous, goal-driven systems represents a fundamental shift in artificial intelligence. This chapter examines the emergence of agentic AI systems that integrate planning, memory, tool use, and iterative reasoning to operate autonomously in complex environments. We trace the architectural progression from statistical models to transformer-based systems, identifying cap
The Path Ahead for Agentic AI: Challenges and Opportunities
-
(Multiomics OR Omics) AND (Pancreatic)
-
Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine
J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.ABSTRACTINTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tum
Organoids in translation: a bench-to-bedside framework for pancreatic cancer precision medicine
J Transl Med. 2026 Jan 6. doi: 10.1186/s12967-025-07596-8. Online ahead of print.
ABSTRACT
INTRODUCTION: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a 5-year survival rate of < 13%. Standard treatments such as FOLFIRINOX or gemcitabine/nab-paclitaxel yield modest response rates, underscoring the urgent need for precision oncology approaches. Patient-derived organoids (PDOs) preserve the genomic, phenotypic, and histopathological features of the source tumor and offer a promising platform for drug screening, biomarker development, and personalized therapy. However, a systematic evaluation of their translational capacities is lacking.
METHODS: A systematic review was conducted according to the PRISMA 2020 guidelines (PROSPERO registration pending) using PubMed, EMBASE, and Cochrane CENTRAL (December 10, 2024) to identify English-language PDAC PDO studies that incorporated therapeutic testing. Ninety-five studies met the inclusion criteria. Data extraction captured >75 variables per study, including spanning culture methodology, therapeutic profiling, biomarker integration, and clinical correlation. A 13-domain weighted Translatability Scoring Framework adapted from Wehling et al. assessed predictive validity, biomarker strength, pharmacogenetics, and clinical trial alignment. Scores ranged from 0 to 5 and were categorized as good (>4.0), moderate (3.0-4.0), or low (<3.0) translational potential.
RESULTS: Of the 95 studies, 70.5% have been published since 2021, reflecting the rapid growth in this field. The mean PDO generation success rate was 89.7%, with the primary tumor tissue being the predominant source (48.4%). Only 24.8% were directly linked to clinical trials and 5.3% incorporated multi-omic profiling. The median translatability score was 3.13 (range, 1.72-4.59): 45.3% of the studies had low translatability, 50.5% moderate, and only 4.2% had good translational potential. High-scoring studies consistently combine multi-omic biomarker platforms, in vivo validation, clinical outcome correlation, and prospective trial integration. Conversely, the weakest domains were pharmacogenetics, endpoint strategies, and biomarker validation, limiting their overall clinical relevance.
CONCLUSIONS: PDOs have demonstrated strong feasibility and in vitro clinical correlation in PDAC; however, their clinical translation remains constrained by limited multi-omic integration, absence of pharmacogenomic modeling, and sparse clinical trial embedding. Standardization of protocols, adoption of harmonized and clinically relevant endpoints, and systematic incorporation of biomarker-driven co-clinical trial frameworks are urgently needed to transition PDOs from promising experimental surrogates to validating precision oncology tools capable of informing therapeutic decision-making in PDAC.
PMID:41495743 | DOI:10.1186/s12967-025-07596-8
-
STAT

-
STAT+: FDA announces sweeping changes to oversight of wearables, AI-enabled devices
LAS VEGAS — The Food and Drug Administration announced Tuesday that it will ease regulation of digital health products, following through on the Trump administration’s promises to deregulate artificial intelligence and promote its widespread use. FDA Commissioner Marty Makary indicated that one of the agency’s priorities is fostering an environment that’s good for investors, and that FDA regulation needs to move “at Silicon Valley speed.” He announced the changes during an address to conferen
STAT+: FDA announces sweeping changes to oversight of wearables, AI-enabled devices
LAS VEGAS — The Food and Drug Administration announced Tuesday that it will ease regulation of digital health products, following through on the Trump administration’s promises to deregulate artificial intelligence and promote its widespread use.
FDA Commissioner Marty Makary indicated that one of the agency’s priorities is fostering an environment that’s good for investors, and that FDA regulation needs to move “at Silicon Valley speed.” He announced the changes during an address to conference attendees at the Consumer Electronics Show.
The agency will soften its approach to the regulation of clinical decision support software, which include AI-enabled products that help doctors navigate diagnoses and treatment options. The agency previously considered products that delivered a single recommendation as FDA-regulated medical devices. Now, those products can enter the market without FDA review as long as they fulfill the agency’s other criteria for escaping regulation.
Continue to STAT+ to read the full story…


© ANDREW CABALLERO-REYNOLDS/AFP via Getty Images